UCB's Doliveux to chair IMI
This article was originally published in Scrip
The Innovative Medicines Initiative, a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has appointed UCB's CEO Roch Doliveux chair of the governing board. UCB has been involved in the IMI since its inception, and Mr Doliveux has been a member of the governing board since May 2010. Mr Doliveux is also a member of EFPIA's board.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.